SYK, which directly binds to and activates FLT3, has been implicated in the pathogenesis of B-cell malignancies, making it a promising therapeutic target. Speaking from the American Society of Hematology (ASH) 2017 Annual Meeting and Exposition in Atlanta, GA, Dr Pratz discusses the study he presented (NCT02323113), which investigated TAK-659, an oral dual SYK/FLT3 inhibitor, for relapsed or refractory acute myeloid leukemia (AML). Keith Pratz, MD, of Johns Hopkins University, Baltimore, MD, covers the promising suppression and clinical responses achieved so far, in FLT3-mutated and FLT3-unmutated patients.
Dual FLT3/SYK oral inhibitor for AML: TAK-659
